Dataset from A 16-week Treatment, Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel-group Study to Assess the Effect of Omalizumab on the Expression of FcεRI Receptors of Blood Basophils and Dendritic Cells in Patients With Severe Persistent Non-atopic Asthma, Uncontrolled Despite Optimal Therapy

This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe persistent asthma, uncontrolled despite optimal therapy.

本研究旨在评估经最优治疗仍未得到有效控制的非特应性重度持续性哮喘成人患者，对比奥马珠单抗（omalizumab）治疗16周后与安慰剂组患者的血液嗜碱性粒细胞、树突状细胞FcεRI受体（FcεRI receptors）表达变化。